These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10720646)

  • 1. Cisplatin-induced emesis in the cat: effect of granisetron and dexamethasone.
    Rudd JA; Tse JY; Wai MK
    Eur J Pharmacol; 2000 Mar; 391(1-2):145-50. PubMed ID: 10720646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Action of 5-HT3 receptor antagonists and dexamethasone to modify cisplatin-induced emesis in Suncus murinus (house musk shrew).
    Sam TS; Cheng JT; Johnston KD; Kan KK; Ngan MP; Rudd JA; Wai MK; Yeung JH
    Eur J Pharmacol; 2003 Jul; 472(1-2):135-45. PubMed ID: 12860482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret.
    Rudd JA; Naylor RJ
    Br J Pharmacol; 1996 May; 118(2):209-14. PubMed ID: 8735616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
    de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
    Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet.
    Grélot L; Le Stunff H; Milano S; Blower PR; Romain D
    J Pharmacol Exp Ther; 1996 Oct; 279(1):255-61. PubMed ID: 8859001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
    Hesketh PJ; Roman A; Hesketh AM; Perez EA; Edelman M; Gandara DR
    Support Care Cancer; 2000 Jan; 8(1):46-8. PubMed ID: 10650897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
    Matsui K; Fukuoka M; Takada M; Kusunoki Y; Yana T; Tamura K; Yoshida T; Iida K; Hirashima T; Tsukada H; Ushijima S; Miyawaki H; Masuda N
    Br J Cancer; 1996 Jan; 73(2):217-21. PubMed ID: 8546909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis.
    Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Yokozaki M; Kodama T
    Jpn J Clin Oncol; 1996 Jun; 26(3):164-8. PubMed ID: 8656557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.
    Anticancer Drugs; 1999 Jun; 10(5):465-70. PubMed ID: 10477166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.
    Latreille J; Stewart D; Laberge F; Hoskins P; Rusthoven J; McMurtrie E; Warr D; Yelle L; Walde D; Shepherd F
    Support Care Cancer; 1995 Sep; 3(5):307-12. PubMed ID: 8520877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
    Perez EA; Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer RH; Fitts D
    Support Care Cancer; 1997 Jan; 5(1):31-7. PubMed ID: 9010987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
    Campos D; Pereira JR; Reinhardt RR; Carracedo C; Poli S; Vogel C; Martinez-Cedillo J; Erazo A; Wittreich J; Eriksson LO; Carides AD; Gertz BJ
    J Clin Oncol; 2001 Mar; 19(6):1759-67. PubMed ID: 11251007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin.
    Rudd JA; Ngan MP; Wai MK; King AG; Witherington J; Andrews PL; Sanger GJ
    Neurosci Lett; 2006 Jan; 392(1-2):79-83. PubMed ID: 16182445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413.
    Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Yokozaki M; Goto K; Miyamoto T; Takafuji J; Kodama T
    Br J Cancer; 1997; 76(1):90-2. PubMed ID: 9218738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?].
    Lehoczky O; Bagaméri A; Sárosi Z; Kulcsár T; Pulay T
    Orv Hetil; 2001 Aug; 142(31):1681-4. PubMed ID: 11556262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
    Latreille J; Pater J; Johnston D; Laberge F; Stewart D; Rusthoven J; Hoskins P; Findlay B; McMurtrie E; Yelle L; Williams C; Walde D; Ernst S; Dhaliwal H; Warr D; Shepherd F; Mee D; Nishimura L; Osoba D; Zee B
    J Clin Oncol; 1998 Mar; 16(3):1174-8. PubMed ID: 9508205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.